中国中西医结合外科杂志
中國中西醫結閤外科雜誌
중국중서의결합외과잡지
CHINESE JOURNAL OF SURGERY OF INTEGRATED TRADITIONAL AND WESTERN MEDICINE
2015年
1期
13-15
,共3页
毛兆光%刘炳胜%徐生根%祝继明%朱慧华%毛晓明
毛兆光%劉炳勝%徐生根%祝繼明%硃慧華%毛曉明
모조광%류병성%서생근%축계명%주혜화%모효명
疏血通注射液%利伐沙班%深静脉血栓形成
疏血通註射液%利伐沙班%深靜脈血栓形成
소혈통주사액%리벌사반%심정맥혈전형성
Shuxuetong injection%rivaroxaban%deep venous thrombosis
目的：探讨疏血通注射液和利伐沙班对髋部手术后血浆内皮素（ET)、血栓素B2（TXB2）和6-酮-前列环素（6-Keto-PEG1a）水平的影响。方法：将68例髋部手术患者随机分为2组，每组34例，疏血通组静脉输注疏血通注射液6 mL/d，利伐沙班组口服利伐沙班10 mg/d。比较2组ET、TXB2、6-Keto-PGFla的变化。结果：疏血通组和利伐沙班组术后第14 d的ET含量较术后第3 d明显降低。术后第14 d两组的血栓素（TXB2）含量较治疗前明显降低，相反6-Keto-PGFla含量较治疗前明显升高。两组间血浆ET、TXB2、6-Keto-PGFla的含量水平差异无统计学意义（P＞0.05）。疏血通注射液组DVT的总发生率为11.8%，利伐沙班组DVT的总发生率为8.8%。两组均为未出现明显不良反应。结论：疏血通注射液与利伐沙班均能安全有效地减少DVT的发生率，其作用机制可能是通过TXB2(TXA2)/6-Keto-PGFla（PGI2）/ET途径实现的。
目的：探討疏血通註射液和利伐沙班對髖部手術後血漿內皮素（ET)、血栓素B2（TXB2）和6-酮-前列環素（6-Keto-PEG1a）水平的影響。方法：將68例髖部手術患者隨機分為2組，每組34例，疏血通組靜脈輸註疏血通註射液6 mL/d，利伐沙班組口服利伐沙班10 mg/d。比較2組ET、TXB2、6-Keto-PGFla的變化。結果：疏血通組和利伐沙班組術後第14 d的ET含量較術後第3 d明顯降低。術後第14 d兩組的血栓素（TXB2）含量較治療前明顯降低，相反6-Keto-PGFla含量較治療前明顯升高。兩組間血漿ET、TXB2、6-Keto-PGFla的含量水平差異無統計學意義（P＞0.05）。疏血通註射液組DVT的總髮生率為11.8%，利伐沙班組DVT的總髮生率為8.8%。兩組均為未齣現明顯不良反應。結論：疏血通註射液與利伐沙班均能安全有效地減少DVT的髮生率，其作用機製可能是通過TXB2(TXA2)/6-Keto-PGFla（PGI2）/ET途徑實現的。
목적：탐토소혈통주사액화리벌사반대관부수술후혈장내피소（ET)、혈전소B2（TXB2）화6-동-전렬배소（6-Keto-PEG1a）수평적영향。방법：장68례관부수술환자수궤분위2조，매조34례，소혈통조정맥수주소혈통주사액6 mL/d，리벌사반조구복리벌사반10 mg/d。비교2조ET、TXB2、6-Keto-PGFla적변화。결과：소혈통조화리벌사반조술후제14 d적ET함량교술후제3 d명현강저。술후제14 d량조적혈전소（TXB2）함량교치료전명현강저，상반6-Keto-PGFla함량교치료전명현승고。량조간혈장ET、TXB2、6-Keto-PGFla적함량수평차이무통계학의의（P＞0.05）。소혈통주사액조DVT적총발생솔위11.8%，리벌사반조DVT적총발생솔위8.8%。량조균위미출현명현불량반응。결론：소혈통주사액여리벌사반균능안전유효지감소DVT적발생솔，기작용궤제가능시통과TXB2(TXA2)/6-Keto-PGFla（PGI2）/ET도경실현적。
Objective To investigate the effect of Shuxuetong injection and Rivaroxaban on the changes of plasma endothelin (ET), thromboxane B2 (TXB2) and 6-keto prostaglandin (6-Keto-PEG1a) levels in the patients after hip orthopedic operation. Methods Sixty-eight cases of hip surgery were randomly divided into two groups(34 cases in each group). Both groups received the same basic treatment, and the Shuxuetong group was treated with Shuxuetong injection 6 mL/d while the Rivaroxaban group was treated with Rivaroxaban 10 mg/d. Results The postoperative fourteenth day’s level of ET of the two group was significantly lower than that of the third day’s. Fourteen days after surgery, the thromboxane TXB2 was significantly lower than pretherapy, on the contrast, the 6-Keto-PGFla was significantly higher than pretherapy. The level of plasma ET, TXB2, or 6-Ke?to-PGFla was of no significant difference between the two groups(P>0.05). The incidence of deep vein thrombo?sis (DVT) in Shuxuetong group was 11.8%, and the incidence of DVT in rivaroxaban group was 8.8%. No obvi?ous adverse reactions were found between the two groups. Conclusion Shuxuetong injection and Rivaroxaban can safely and effectively reduce the incidence of DVT, and its mechanism may be through the TXB2 (TXA2)/6-Keto-PGFla (PGI2)/ET pathway.
